OBJECTIVES: We sought to identify chloroquine-resistant Plasmodium falciparum parasites among 66 travellers who presented in the UK with malaria. METHODS: A multiplex real-time PCR assay was devised to identify wild-type and two distinct chloroquine-resistance-associated alleles of the pfcrt gene. RESULTS: Those with documented use of chloroquine/proguanil prophylaxis were more likely to carry parasites with resistance-associated alleles of pfcrt than were patients who had been using antimalarials other than chloroquine (92.9% versus 37.5%; P = 0.011). We also found evidence that people reporting optimum compliance with chloroquine prophylaxis during malaria exposure were more common among malaria cases than were those reporting optimum compliance with other regimens (OR 3.85, 95% CI 1.61-9.69; P = 0.0008). CONCLUSIONS: Chloroquine, known to be failing as therapy for falciparum malaria worldwide, is also failing to provide adequate malaria prophylaxis for travellers.
OBJECTIVES: We sought to identify chloroquine-resistant Plasmodium falciparum parasites among 66 travellers who presented in the UK with malaria. METHODS: A multiplex real-time PCR assay was devised to identify wild-type and two distinct chloroquine-resistance-associated alleles of the pfcrt gene. RESULTS: Those with documented use of chloroquine/proguanil prophylaxis were more likely to carry parasites with resistance-associated alleles of pfcrt than were patients who had been using antimalarials other than chloroquine (92.9% versus 37.5%; P = 0.011). We also found evidence that people reporting optimum compliance with chloroquine prophylaxis during malaria exposure were more common among malaria cases than were those reporting optimum compliance with other regimens (OR 3.85, 95% CI 1.61-9.69; P = 0.0008). CONCLUSIONS:Chloroquine, known to be failing as therapy for falciparum malaria worldwide, is also failing to provide adequate malaria prophylaxis for travellers.
Authors: A P H A Moers; R L Hallett; R Burrow; H D F H Schallig; C J Sutherland; A van Amerongen Journal: Antimicrob Agents Chemother Date: 2014-11-03 Impact factor: 5.191
Authors: J I Thwing; C O Odero; F O Odhiambo; K O Otieno; S Kariuki; R Ord; C Roper; M McMorrow; J Vulule; L Slutsker; R D Newman; M J Hamel; M Desai Journal: Trop Med Int Health Date: 2009-01-28 Impact factor: 2.622
Authors: Yan He; Susana Campino; Ernest Diez Benavente; David C Warhurst; Khalid B Beshir; Inke Lubis; Ana Rita Gomes; Jun Feng; Wang Jiazhi; Xiaodong Sun; Fang Huang; Lin-Hua Tang; Colin J Sutherland; Taane G Clark Journal: PLoS One Date: 2019-03-18 Impact factor: 3.240
Authors: Charlotte A Lanteri; Suwanna Chaorattanakawee; Chanthap Lon; David L Saunders; Wiriya Rutvisuttinunt; Kritsanai Yingyuen; Ian Bathurst; Xavier C Ding; Stuart D Tyner Journal: Antimicrob Agents Chemother Date: 2014-07-21 Impact factor: 5.191
Authors: Nahla B Gadalla; Salah Eldin Elzaki; Ebtihal Mukhtar; David C Warhurst; Badria El-Sayed; Colin J Sutherland Journal: Malar J Date: 2010-03-12 Impact factor: 2.979
Authors: Colin J Sutherland; Helen Fifer; Richard J Pearce; Faisal bin Reza; Meredydd Nicholas; Thomas Haustein; Njah E Njimgye-Tekumafor; Justin F Doherty; Philip Gothard; Spencer D Polley; Peter L Chiodini Journal: Antimicrob Agents Chemother Date: 2009-05-11 Impact factor: 5.191